Global Messenger RNA Market

Global Messenger RNA Market Size Insights Forecasts to 2035

• Global Messenger RNA Market Size Is Expected to Grow at a CAGR of Around 11.3% from 2025 to 2035.
• Global Messenger RNA Market Size Is Expected to Reach a Significant Share by 2035     
• Asia-Pacific is expected to grow the fastest during the forecast period.

According to a research report published by Decisions Advisors and Consulting, The Global Messenger RNA Market Size Is Expected To Hold A Significant Share By 2035, At A CAGR Of 11.3% During The Forecast Period 2025-2035. The global messenger RNA market will create future opportunities through its expansion into rare diseases and personalized oncology therapies and development of innovative delivery technologies and entry into emerging markets and establishment of strategic collaborations and growth of R&D and manufacturing infrastructure through government and private sector funding.

 

Market Overview

The global messenger RNA (mRNA) market refers to the market for mRNA-based technologies used in vaccines and therapeutics that instruct cells to produce specific proteins to prevent or treat diseases. The development of mRNA platforms has attracted widespread interest because these platforms can be developed quickly and they deliver effective solutions for treating infectious diseases and cancer and rare genetic disorders. The market has experienced growth because government support and delivery system innovations through lipid nanoparticles and biotechnology companies have established strategic partnerships. The combination of rising R&D investments and increased public knowledge about mRNA and the growth of manufacturing facilities across the globe has led to wider adoption. North America dominates the market while Asia-Pacific shows high growth potential because both regions provide significant opportunities for development in the advancing healthcare industry.

 

Report Coverage

This research report categorizes the messenger RNA market based on various segments and regions, forecasts revenue growth, and analyzes trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the messenger RNA market. Recent market developments and competitive strategies such as expansion, type launch, development, partnership, merger, and acquisition, have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segment of the messenger RNA market.

 

Driving Factors

The global messenger RNA market exists because people need more vaccines and therapeutics while mRNA technology continues to advance and lipid nanoparticles deliver innovative treatments. Government backing and growing biotechnology investments together with clinical research expansion and personalized medicine and oncology breakthroughs, drive market growth, which helps develop next-generation mRNA technologies.

 

Restraining Factors

The global messenger RNA market faces multiple obstacles that include high development and manufacturing costs, complicated storage and distribution requirements, regulatory challenges, potential safety concerns, and lack of awareness in emerging regions which together create barriers to market adoption.

 

Market Segmentation

The messenger RNA market share is classified into type and application.

 

• The prophylactic mRNA segment accounted for the largest share in 2024 and is anticipated to grow at a significant CAGR during the forecast period.           

Based on the type, the messenger RNA market is divided into prophylactic mRNA and therapeutic mRNA. Among these, the prophylactic mRNA segment accounted for the largest share in 2024 and is anticipated to grow at a significant CAGR during the forecast period. The worldwide requirement for preventive vaccines which includes COVID-19 and influenza vaccines together with strong government vaccination programs and rapid development times and ongoing mRNA technology improvements. These factors drive large-scale production which results in high market adoption and ongoing market expansion that creates a significant market share together with an expected compound annual growth rate.  

       

• The infectious diseases segment accounted for the highest market revenue in 2024 and is anticipated to grow at a significant CAGR during the forecast period.     

Based on the application, the messenger RNA market is divided into infectious diseases, oncology, rare genetic diseases, respiratory diseases, and others. Among these, the infectious diseases segment accounted for the highest market revenue in 2024 and is anticipated to grow at a significant CAGR during the forecast period. The worldwide need for vaccines that protect against COVID-19 and influenza and other viral diseases drives vaccine demand. The combination of strong government immunization programs and rapid mRNA vaccine development together with increased public awareness results in high product adoption and large-scale production and ongoing innovation which generates both maximum revenue and substantial future growth.  

 

Regional Segment Analysis of the Messenger RNA Market

• North America (U.S., Canada, Mexico) 
• Europe (Germany, France, U.K., Italy, Spain, Rest of Europe)
• Asia-Pacific (China, Japan, India, Rest of APAC)
• South America (Brazil and the Rest of South America) 
• The Middle East and Africa (UAE, South Africa, Rest of MEA)

 

North America is anticipated to hold the largest share of the messenger RNA market over the predicted timeframe.

North America is anticipated to hold the largest share of the messenger RNA market over the predicted timeframe. The combination of advanced biotechnology infrastructure and the work of leading mRNA developers with the government support that tests vaccines and the development of vaccines and therapeutics which continues to occur.

 

Asia-Pacific is expected to grow at a rapid CAGR in the messenger RNA market during the forecast period. The market experiences rapid growth because of four main drivers which include increasing biotechnology investments and government support for vaccine manufacturing combined with the growing use of mRNA-based drugs and the expansion of clinical research and new production facilities that countries like China and India and Japan are establishing.

 

Competitive Analysis:

The report offers the appropriate analysis of the key organizations/companies involved within the messenger RNA market, along with a comparative evaluation primarily based on their type of offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes type development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

 

List of Key Companies

• Pfizer Inc.
• Moderna Inc.
• BioNTech SE
• CureVac N.V.
• Sanofi
• GlaxoSmithKline plc (GSK)
• AstraZeneca plc
• Arcturus Therapeutics
• Sangamo Therapeutics
• Daiichi Sankyo Company, Limited
• Others

 

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting and Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

 

Market Segment

This study forecasts revenue at global, regional, and country levels from 2020 to 2035. Decisions Advisors has segmented the messenger RNA market based on the below-mentioned segments: 

 

Global Messenger RNA Market, By Type

• Prophylactic mRNA
• Therapeutic mRNA

 

Global Messenger RNA Market, By Application

• Infectious Diseases
• Oncology
• Rare Genetic Diseases
• Respiratory Diseases
• Others

 

Global Messenger RNA Market, By Regional Analysis

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  •  South Korea
  • Australia
  • Rest of Asia Pacific
• South America
  • Brazil
  • Argentina
  • Rest of South America
• Middle East & Africa
  • UAE
  • Saudi Arabia
  • Qatar
  • South Africa
  • Rest of the Middle East & Africa

 

Frequently Asked Questions (FAQ)

 

1. What is the CAGR of the messenger RNA market over the forecast period?

A: The global messenger RNA market is projected to expand at a CAGR of 11.3% during the forecast period.

 

2. Which region holds the largest share of the messenger RNA market?

A: North America is anticipated to hold the largest share of the messenger RNA market over the predicted timeframe.

 

3. Who are the top 10 companies operating in the global messenger RNA market?

A: Pfizer Inc., Moderna Inc., BioNTech SE, CureVac N.V., Sanofi, GlaxoSmithKline plc (GSK), AstraZeneca plc, Arcturus Therapeutics, Sangamo Therapeutics, Daiichi Sankyo Company, Limited

 

4. What are the market trends in the messenger RNA market?

A: The messenger RNA market is experiencing growth because of various factors which include expanded therapeutic applications and the growth of oncology research and improvements in delivery technology and the establishment of strategic partnerships and the governmental support for vaccine development.